Skip to main content

Table 2 Three-years survival rates of univariate analysis according to the prognostic factors

From: Radical radiotherapy in patients with cervix uteri carcinoma: experience of Ondokuz Mayis University

 LRFFSDMFSPFSOS
%P%P%P%P
FIGO stage 0.003 0.26 0.01 0.03
  ≤ IIA100 100 100 100 
 IIB95.0 75.9 75.9 88.1 
 III71.3 65.0 46.0 52.6 
 IV50.0 100 50.0 100 
Node metastasis 0.42 0.15 0.14 0.09
 Negative95.2 83.3 79.2 91.7 
 Positive79.2 69.7 57.8 65.9 
Parametrial invasion 0.95 0.42 0.60 0.84
 Positive92.1 71.7 68.2 73.5 
 Negative75.0 90.9 68.1 88.9 
Tumor size 0.94 0.19 0.08 0.11
  ≤ 5 cm90.0 80.6 71.7 79.2 
  > 5 cm84.1 68.0 61.0 56.8 
Initial tumor volume 0.39 0.76 0.32 0.53
  < 65 cm386.5 75.7 67.3 62.4 
  ≥ 65 cm388.4 77.3 67.7 63.7 
HR-CTV 0.18 0.39 0.06 0.12
  ≤ 30 cm395.2 81.7 81.7 84.6 
  > 30 cm375.9 68.8 49.6 70.0 
Chemothrapy 0.34 0.77 0.64 0.82
  ≤ 4 course74.3 71.1 49.5 87.5 
  ≥ 5 course94.4 78.2 76.2 73.9 
D90 (EQD2) 0.01 0.95 0.23 0.17
  ≤ 90 Gy65.0 67.7 41.4 72.9 
  > 90 Gy100 78.6 78.6 80.2 
  1. LRFFS loco-regional failure-free survival, PFS progression-free survival, DMSF distant metastasis-free survival, OS overall survival, FIGO Fédération Internationale de Gynécologie et d’Obstétrique, HR-CTV High risk clinical target volume